Reuters: Regulatory News: Merrimack lung cancer drug fails goal in one mid-stage trial group

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Merrimack lung cancer drug fails goal in one mid-stage trial group Apr 4th 2013, 12:31 April 4 | Thu Apr 4, 2013 8:31am EDT April 4 (Reuters) - Merrimack Pharmaceuticals Inc said one of three patient groups in a mid-stage trial of its experimental lung cancer drug failed to meet the main goal of improving survival rates after four months of treatment without the disease worsening. The group was administered the drug, MM-121, in combination with erlotinib, an approved cancer treatment, for non-small cell lung cancer. The main goal was to show a 40 percent improvement in progression-free survival after four months. The drug is also being evaluated in two other lung-cancer patient groups, and in separate studies for ovarian and breast cancer.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions